[Congressional Record Volume 148, Number 101 (Tuesday, July 23, 2002)]
[House]
[Pages H5093-H5094]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
CORPORATE GREED
The SPEAKER pro tempore. Pursuant to the order of the House of
January 23, 2002, the gentleman from Ohio (Mr. Brown) is recognized
during morning hour debates for 5 minutes.
Mr. BROWN of Ohio. Mr. Speaker, the Bush administration has very
close ties to the prescription drug industry. In and of itself, that
might not be a problem. Part of any administration's job is to support
American industry, so long as it coincides with the best interests of
the American people.
That is, unfortunately, where the Bush administration runs into
problems. The best interests of the American people should outweigh the
interests of industry, but too often with this administration, the drug
industry prevails at the expense of American consumers.
Last year, for instance, prescription drug costs increased 17
percent, while the inflation rate was only 1.6 percent. Rising drug
costs have fueled double-digit increases in health insurance premiums.
Rises in drug costs are putting State budgets in the red. Rising drug
costs are bankrupting seniors on fixed incomes.
The Bush administration's response to this situation? They recently
released a ``study'' arguing that American consumers must continue to
pay the highest prices in the world for prescription drugs. If we do
not, the study said, medical research and development will dry up. This
study is available online at www.hhs.gov.
It could just as easily, however, appear at www.phrma.org, the drug
industry association's Web site. If Members had any questions about how
closely aligned the administration is with the drug industry, this
study makes it clear they are in lockstep.
I wonder, Mr. Speaker, if it is any coincidence that this study comes
out of the Department of Health and Human Services' Planning Office,
which is managed by a former employee of, you guessed it, the drug
industry.
This study says the best bet for American consumers is the status
quo. If we do anything about price, this study, the administration, or
the drug industry, and it all, unfortunately, seems like the same thing
too often, if we do anything about price, the administration says, we
will be responsible in this country for killing research and
development in the drug industry.
It is a pretty difficult sell to claim this when we consider that the
drug industry has topped, or in terms of profitability, it has been the
most profitable industry in America for 20 years running, return on
price, return on sales, return on equity. While the overall profits of
Fortune 500 companies declined 53 percent last year, the top 10
drugmakers increased profits by 33 percent last year.
Drug companies spend twice as much on marketing and administration as
they do on research and development. U.S. tax dollars fund almost half
of the research that the drug industry does, but American consumers are
supposed to be so grateful that they are supposed to gratefully pay
twice for that R&D. We are supposed to thank the drug industry for
charging us prices two and three and four times what prices are in
every other country in the world.
To explain this, look what happened last month. Last month, the drug
industry wrote a prescription drug coverage bill for the Republican
leadership that was introduced in the Committee on Energy and Commerce
to give a prescription drug plan for Americans. The drug industry wrote
the bill.
The Republicans started a hearing. The Republicans, as we were
marking up this drug industry bill sponsored by Republicans, our
committee recessed at 5 o'clock so Members of the committee, Republican
Members of the committee, could go off to a fundraiser underwritten by
the drug companies, chaired by the CEO of GlaxoSmithKline, a British
drug company, who gave $250,000. The next morning, the Republicans and
all of us met again to work on this drug bill. Every pro-consumer
amendment was defeated by the drug industry and by the Republicans.
After this bill then passed the committee and passed the House of
Representatives, the drug industry spent,
[[Page H5094]]
through a group called United Seniors Association, but paid by the drug
industry, spent $3 million on an ad campaign thanking those Republican
Members for passing it and thanking them for their concern for
America's seniors. So the drug industry wrote the bill, the Republicans
passed the bill, the drug industry gave money to the Republicans while
the bill was being passed, and then the drug industry ran TV ads
thanking the Republican Members and congratulating them on a job well
done.
The Bush administration then, no surprise here, followed suit by
claiming that seniors' best hope for drug coverage is the Republican
bill.
Now, why is this? Why should the drug industry have this kind of
influence here? Well, over the last 12 years, the drug industry's
lobbying expenditures have increased 800 percent. In the 2000 election
cycle, the drug industry contributed $26 million to candidates running
for office, the overwhelming majority of which to Republicans. The
industry contributed $625,000 to the Bush-Cheney inaugural. So far in
this election cycle, the drug industry has contributed $14.6 million in
political donations, the vast majority of which to Republicans.
This may explain, Mr. Speaker, why the administration is working so
hard for the drug industry, but it begs the question: Is what is good
for the drug industry in the best interests of the American people?
____________________